Clinical Trials Directory

Trials / Completed

CompletedNCT01185925

Exercise Oscillatory Breathing and Sildenafil in Heart Failure

PDE5-Inhibition With Sildenafil Reverses Exercise Oscillatory Breathing in Chronic Heart Failure: a Long-Term Cardiopulmonary Exercise Testing Placebo-Controlled Study

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
32 (actual)
Sponsor
University of Milan · Academic / Other
Sex
Male
Age
30 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Exercise oscillatory breathing (EOB) is a ventilatory abnormality that occurs in approximately 20% of heart failure (HF) patients and carries a very unfavourable prognosis. Pathophysiology seems quite complex and putative mechanisms include increased pulmonary capillary pressure and pulmonary vasoconstriction, circulatory blood-flow fluctuations in the pulmonary arterial system and instability of ventilatory control. Inhibition of the phosphodiesterase 5 (PDE5) isoenzyme favourably regulates pulmonary vascular tone and permeability through over signaling of the endothelial nitric oxide pathway. The investigators tested the hypothesis that sildenafil would reverse the EOB pattern in patients with HF and pulmonary hypertension.

Conditions

Interventions

TypeNameDescription
DRUGSildenafilSildenafil, 50 mg 3 times/day
DRUGPlaceboPlacebo

Timeline

Start date
2008-04-01
Primary completion
2009-12-01
Completion
2010-06-01
First posted
2010-08-20
Last updated
2011-08-05

Source: ClinicalTrials.gov record NCT01185925. Inclusion in this directory is not an endorsement.

Exercise Oscillatory Breathing and Sildenafil in Heart Failure (NCT01185925) · Clinical Trials Directory